antibody_therapeutics

This month provided not just one, but two FDA approvals for antibody drugs treating patients with paroxysmal nocturnal hemoglobinuria (PNH)!

Antibody-drug conjugates unite antibody precision with cytotoxic potency. Biointron explains how ADCs deliver targeted therapies that revolutionize cancer treatment.

Therapeutic antibodies have transformed modern medicine. Biointron reviews their evolution, clinical applications, and impact on shaping today’s treatment landscape.

Immunostimulatory ADCs (iADCs), also known as immune-stimulating antibody conjugates (iSACs), arean advanced form of targeted cancer therapy. They not only activate innate immunity but also stimulate adaptive immunity, providing a dual therapeutic effect to eliminate tumor cells. They combine

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Blood disorders, including anemias, coagulopathies, leukemias, lymphomas, and thrombocytopenias, disrupt the normal functioning of blood components. Antibody therapeutics, such as monoclonal antibodies (mAbs), have transformed treatment approaches by offering targeted, high-specificity interventions.

Discover how immune checkpoint inhibitors like PD-1 and CTLA-4 blockers are transforming cancer treatment, including synergies with antibody-based therapeutics.

Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.